Saladax Regains Rights to My5-FU Assay from Myriad | GenomeWeb

NEW YORK (GenomeWeb News) – Saladax Biomedical today said that it will offer its My5-FU assay as part of its MyCare service offering later this year after regaining marketing rights to the test from Myriad Genetics.

The Bethlehem, Pa.-based firm said that it would begin offering the assay, which is used to help guide optimized dosing of infusional 5-fluorouracil to patients, later this year when its CLIA lab commences operations in June. 5-FU is used to treat several types of cancers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."